Valink Therapeutics and Nona Biosciences Form Strategic Alliance to Accelerate Novel Biologics Discovery
Valink Therapeutics (“Valink”), a private biotechnology company developing next-generation therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities, and Nona Biosciences (“Nona”), a global biotechnology company providing integrated solutions for biological drug discovery and development from “Idea to IND” (I to I®), today announced the formation of a strategic biologics discovery alliance. The collaboration branded “Biology to Bispecific” (B2B)™, unites both companies’ complementary platforms and expertise to accelerate the creation of innovative bispecific antibodies and bispecific ADCs. With an initial focus on bsADCs in solid tumors, the collaboration will expand Valink’s internal therapeutic pipeline and contribute to future co-development and licensing opportunities.
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board
Valink Therapeutics, a biopharmaceutical company focused on discovering and developing innovative bispecific antibody-drug conjugates (bsADCs) to transform the treatment of cancer and other diseases, has appointed Martin D. Williams as Chair of its Board of Directors. The company also named its Scientific Advisory Board, which assembles experts in the discovery, development, manufacture and commercialization of ADCs and bispecific therapeutics.
